Free Trial

Crinetics Pharmaceuticals (CRNX) Short Interest Ratio & Short Volume

Crinetics Pharmaceuticals logo
$28.53 -0.71 (-2.43%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$29.20 +0.66 (+2.33%)
As of 08/6/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals Short Interest Data

Crinetics Pharmaceuticals (CRNX) has a short interest of 12.24 million shares. This marks a 13.12% increase in short interest from the previous month. The short interest ratio (days to cover) is 15.4, indicating that it would take 15.4 days of the average trading volume of 881,542 shares to cover all short positions.

Current Short Interest
12,240,000 shares
Previous Short Interest
10,820,000 shares
Change Vs. Previous Month
+13.12%
Dollar Volume Sold Short
$389.60 million
Short Interest Ratio
15.4 Days to Cover
Last Record Date
July 15, 2025
Outstanding Shares
93,630,000 shares
Percentage of Shares Shorted
13.07%
Today's Trading Volume
1,212,519 shares
Average Trading Volume
881,542 shares
Today's Volume Vs. Average
138%
Short Selling Crinetics Pharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CRNX Short Interest Over Time

CRNX Days to Cover Over Time

CRNX Percentage of Float Shorted Over Time

Crinetics Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202512,240,000 shares $389.60 million +13.1%N/A15.4 $31.83
6/30/202510,820,000 shares $311.18 million +4.8%12.1%12.8 $28.76
6/15/202510,320,000 shares $327.87 million +1.1%11.6%11.5 $31.77
5/31/202510,210,000 shares $312.32 million +0.5%11.7%10.6 $30.59
5/15/202510,160,000 shares $317.09 million +3.3%11.7%9.8 $31.21
4/30/20259,840,000 shares $328.56 million +2.2%N/A9.7 $33.39
4/15/20259,630,000 shares $285.63 million +12.8%11.0%9.6 $29.66
3/31/20258,540,000 shares $286.43 million +9.9%9.8%7.8 $33.54
3/15/20257,770,000 shares $267.83 million -4.2%8.9%7.9 $34.47
2/28/20258,110,000 shares $290.18 million +4.0%9.3%8.6 $35.78
2/15/20257,800,000 shares $274.64 million +5.7%8.9%9.1 $35.21
1/31/20257,380,000 shares $297.41 million +2.9%N/A8.7 $40.30
1/15/20257,170,000 shares $263.35 million +3.6%N/A8.9 $36.73
12/31/20246,920,000 shares $353.82 million +10.7%N/A8.9 $51.13
12/15/20246,250,000 shares $335.38 million +4.0%N/A8.4 $53.66
11/30/20246,010,000 shares $343.77 million -7.5%N/A8.4 $57.20
11/15/20246,500,000 shares $355.68 million -6.3%N/A9.1 $54.72
10/31/20246,940,000 shares $388.36 million +5.3%N/A10.5 $55.96
10/15/20246,590,000 shares $379.58 million -2.8%N/A9.8 $57.60
9/30/20246,780,000 shares $346.46 million +11.0%N/A10.3 $51.10
9/15/20246,110,000 shares $328.72 million -1.8%N/A8.2 $53.80
8/31/20246,220,000 shares $330.03 million -3.9%N/A8.3 $53.06
8/15/20246,470,000 shares $339.87 million +5.7%N/A8 $52.53
7/31/20246,120,000 shares $325.09 million -7.0%N/A6.6 $53.12
7/15/20246,580,000 shares $356.24 million +12.1%N/A7 $54.14
6/30/20245,870,000 shares $262.92 million +0.2%N/A6.5 $44.79
6/15/20245,860,000 shares $265.63 million +16.5%N/A6.7 $45.33
5/31/20245,030,000 shares $223.38 million +2.4%N/A5.6 $44.41
5/15/20244,910,000 shares $247.91 million No ChangeN/A5.5 $50.49
4/30/20244,910,000 shares $215.16 million -5.9%N/A5.9 $43.82
4/15/20245,220,000 shares $228.01 million +6.3%N/A6.5 $43.68
3/31/20244,910,000 shares $229.84 million -2.0%N/A6.1 $46.81
3/15/20245,010,000 shares $195.04 million +5.7%N/A6.7 $38.93
2/29/20244,740,000 shares $194.06 million +5.1%N/A6 $40.94
2/15/20244,510,000 shares $166.51 million -11.1%N/A5.8 $36.92
1/31/20245,070,000 shares $184.95 million -0.8%N/A6.2 $36.48
1/15/20245,110,000 shares $190.04 million -0.6%N/A6 $37.19
12/31/20235,140,000 shares $182.88 million -13.6%N/A5.9 $35.58
12/15/20235,950,000 shares $205.04 million -6.7%N/A6.4 $34.46
11/30/20236,380,000 shares $202.82 million +2.9%N/A4 $31.79
Musk’s Project Colossus could mint millionaires (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.

All the details are waiting for you now — but you need to act before the September 1st funding windo
11/15/20236,200,000 shares $179.06 million -7.6%N/A4 $28.88
10/31/20236,710,000 shares $196.54 million -1.5%N/A4.4 $29.29
10/15/20236,810,000 shares $198.24 million +16.4%N/A4.7 $29.11
9/30/20235,850,000 shares $173.98 million +43.7%N/A4.1 $29.74
9/15/20234,070,000 shares $120.02 million -10.4%N/A3.1 $29.49
8/31/20234,540,000 shares $78.63 million +21.4%N/A5.2 $17.32
8/15/20233,740,000 shares $62.53 million +11.0%N/A7.9 $16.72
7/31/20233,370,000 shares $64.03 million -2.9%N/A7.2 $19.00
7/15/20233,470,000 shares $70.68 million +1.5%N/A7.2 $20.37
6/30/20233,420,000 shares $61.63 million +4.0%N/A7.6 $18.02
6/15/20233,290,000 shares $68.33 million No ChangeN/A7 $20.77
5/31/20233,290,000 shares $71.82 million -4.4%N/A7.2 $21.83
5/15/20233,440,000 shares $76.82 million -18.9%N/A7.7 $22.33
4/30/20234,240,000 shares $82.85 million -1.2%N/A9.9 $19.54
4/15/20234,290,000 shares $68.34 million -6.3%N/A10.6 $15.93
3/31/20234,580,000 shares $73.55 million +12.3%N/A10.8 $16.06
3/15/20234,080,000 shares $70.14 million +12.1%N/A10.1 $17.19
2/28/20233,640,000 shares $71.49 million +7.4%N/A8.9 $19.64
2/15/20233,390,000 shares $67.70 million -4.0%N/A8.8 $19.97
1/31/20233,530,000 shares $69.22 million -5.4%N/A9.3 $19.61
1/15/20233,730,000 shares $67.29 million No ChangeN/A11.1 $18.04
12/30/20223,730,000 shares $68.26 million +3.3%N/A11.7 $18.30
12/15/20223,610,000 shares $58.63 million -5.3%N/A12.1 $16.24
11/30/20223,810,000 shares $68.08 million -1.3%N/A14.3 $17.87
11/15/20223,860,000 shares $70.41 million -3.7%N/A14.3 $18.24
10/31/20224,010,000 shares $74.02 million -1.7%N/A14.4 $18.46
10/15/20224,080,000 shares $72.05 million +1.5%N/A15 $17.66
9/30/20224,020,000 shares $78.95 million +3.1%N/A15.6 $19.64
9/15/20223,900,000 shares $83.34 million +9.9%N/A14 $21.37
8/31/20223,550,000 shares $67.02 million +13.4%N/A12.3 $18.88
8/15/20223,130,000 shares $70.02 million +12.6%N/A10.3 $22.37
7/31/20222,780,000 shares $53.40 million -2.1%N/A8.9 $19.21
7/15/20222,840,000 shares $58.82 million -1.1%N/A9 $20.71
6/30/20222,870,000 shares $53.53 million +5.9%N/A8.3 $18.65
6/15/20222,710,000 shares $47.86 million +8.8%N/A7.4 $17.66
5/31/20222,490,000 shares $41.71 million +2.1%N/A7.5 $16.75
5/15/20222,440,000 shares $45.75 million +11.9%N/A7.9 $18.75
4/30/20222,180,000 shares $44.30 million -18.1%N/A7.9 $20.32
4/15/20222,660,000 shares $69.16 million +0.8%N/A9.5 $26.00
3/31/20222,640,000 shares $57.95 million +13.3%N/A10.7 $21.95
3/15/20222,330,000 shares $44.46 million +10.4%6.2%9.6 $19.08
2/28/20222,110,000 shares $42.24 million +0.5%5.6%8.1 $20.02
2/15/20222,100,000 shares $41.43 million +23.5%5.6%7.6 $19.73
1/31/20221,700,000 shares $32.11 million +39.3%N/A6.1 $18.89
1/15/20221,220,000 shares $29.29 million -6.9%N/A4.3 $24.01
12/31/20211,310,000 shares $37.22 million +12.0%N/A4.1 $28.41
12/15/20211,170,000 shares $29.45 million +18.1%N/A3.8 $25.17
11/30/2021990,900 shares $27.07 million -1.9%N/A3.6 $27.32
11/15/20211,010,000 shares $27.26 million -13.7%N/A3.8 $26.99
10/29/20211,170,000 shares $29.17 million -17.0%3.4%4.4 $24.93
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond (Ad)

Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).

Click here for the names of our three top stocks to own this year (no purchase necessary).
10/15/20211,410,000 shares $27.48 million -4.7%4.8%5.7 $19.49
9/30/20211,480,000 shares $31.15 million +16.5%5.0%8.5 $21.05
9/15/20211,270,000 shares $29.85 million -3.1%4.3%6.7 $23.50
8/31/20211,310,000 shares $30.88 million +5.7%4.7%6.7 $23.57
8/13/20211,240,000 shares $27.60 million -4.6%4.4%6.3 $22.26
7/30/20211,300,000 shares $23.37 million -0.8%4.9%7.8 $17.98
7/15/20211,310,000 shares $25.82 million -3.7%4.5%8.2 $19.71
6/30/20211,360,000 shares $25.64 million +2.3%4.7%7.9 $18.85
6/15/20211,330,000 shares $24.25 million -8.3%4.6%7.9 $18.23
5/28/20211,450,000 shares $25.45 million -4.6%5.0%10.2 $17.55
5/14/20211,520,000 shares $24.17 million -0.7%N/A12 $15.90
4/30/20211,530,000 shares $27.17 million -0.7%N/A11.1 $17.76
4/15/20211,540,000 shares $25.29 million +2.0%N/A11.1 $16.42
3/31/20211,510,000 shares $23.31 million -2.6%N/A11 $15.44
3/15/20211,550,000 shares $26.24 million +1.3%N/A11.1 $16.93
2/26/20211,530,000 shares $23.03 million +10.9%N/A11.2 $15.05
2/12/20211,380,000 shares $23.78 million -7.4%N/A9 $17.23
1/29/20211,490,000 shares $22.22 million +2.1%N/A9.5 $14.91
1/15/20211,460,000 shares $21.58 million +1.4%N/A8.3 $14.78
12/31/20201,440,000 shares $19.71 million +9.9%N/A8.2 $13.69
12/15/20201,310,000 shares $17.99 million +0.8%N/A8.1 $13.73
11/30/20201,300,000 shares $18.67 million +3.2%N/A8.8 $14.36
11/15/20201,260,000 shares $16.23 million +7.7%N/A9.1 $12.88
10/30/20201,170,000 shares $14.60 million -14.6%N/A9.9 $12.48
10/15/20201,370,000 shares $22.15 million -3.5%N/A13.2 $16.17
9/30/20201,420,000 shares $22.25 million +2.2%N/A14.3 $15.67
9/15/20201,390,000 shares $22.27 million -3.5%N/A8.7 $16.02
8/31/20201,440,000 shares $23.08 million -0.7%N/A7.6 $16.03
8/14/20201,450,000 shares $22.05 million -2.7%N/A7.1 $15.21

CRNX Short Interest - Frequently Asked Questions

What is Crinetics Pharmaceuticals' current short interest?

Short interest is the volume of Crinetics Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 12,240,000 shares of CRNX short. Learn More on Crinetics Pharmaceuticals' current short interest.

What is a good short interest ratio for Crinetics Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRNX shares currently have a short interest ratio of 15.0. Learn More on Crinetics Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Crinetics Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Crinetics Pharmaceuticals: Simplex Trading LLC, Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Crinetics Pharmaceuticals' short interest increasing or decreasing?

Crinetics Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 12,240,000 shares, an increase of 13.1% from the previous total of 10,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Crinetics Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Crinetics Pharmaceuticals: QIAGEN N.V. (2.93%), Viatris Inc. (3.32%), Ascendis Pharma A/S (4.46%), BridgeBio Pharma, Inc. (10.26%), Verona Pharma PLC American Depositary Share (4.77%), Blueprint Medicines Corporation (5.95%), Legend Biotech Corporation Sponsored ADR (4.57%), Roivant Sciences Ltd. (10.56%), Regencell Bioscience Holdings Limited (9.57%), Elanco Animal Health Incorporated (4.75%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks.

What does it mean to sell short Crinetics Pharmaceuticals stock?

Short selling CRNX is an investing strategy that aims to generate trading profit from Crinetics Pharmaceuticals as its price is falling. CRNX shares are trading down $0.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Crinetics Pharmaceuticals?

A short squeeze for Crinetics Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRNX, which in turn drives the price of the stock up even further.

How often is Crinetics Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRNX, twice per month. The most recent reporting period available is July, 15 2025.




This page (NASDAQ:CRNX) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners